Godavari Biorefineries Ltd Q3 FY2025-26 Earnings Conference Call
•February 19, 2026
0
Why It Matters
The earnings beat and strategic investments signal a shift toward higher‑margin bio‑chemicals, enhancing Godavari’s growth trajectory and resilience amid volatile ethanol markets.
Key Takeaways
- •Q3 EBITDA up 14% YoY, margins expanding significantly.
- •Profit before tax surged 152% YoY as finance costs fell 48%.
- •Bio‑chemical EBITDA margin rose to 7% from 4.5% last year.
- •Secured US patent for anti‑cancer molecule; launched Sudgen Therapeutics subsidiary.
- •Capex plan targets 75% bio‑chemicals, 25% ethanol by FY29.
Summary
Godavari Biorefineries Ltd held its Q3 FY2025‑26 earnings conference call, presenting results for the quarter and the nine‑month period. Chairman‑MD Sameer Somaya and CFO Ashish Sinha highlighted a turnaround in profitability, with EBITDA rising roughly 14% year‑on‑year and a notable expansion in margins across the business.
The company reported a 152% jump in profit before tax, driven by operating leverage, an improved product mix and a 48% reduction in finance costs. Bio‑chemical operations lifted the overall earnings profile, delivering an EBITDA margin of 7% versus 4.5% a year earlier, while the ethanol segment faced softness amid rising cane prices. Revenue growth remained modest, but earnings quality improved markedly, turning a prior‑year EBITDA loss into a Rs 47.2 crore profit for the nine‑month span.
Strategic milestones were emphasized, including the grant of a U.S. patent for a novel anti‑cancer molecule and the formation of Sudgen Therapeutics LLC to commercialize the IP. The firm also advanced its DME‑to‑CO₂ pilot, deepened a partnership with Synthoma on bio‑based butyl acrylate, and expanded its consumer brand Jeevana. Management outlined a capital allocation roadmap that earmarks 75% of FY29 capex for bio‑chemical capacity and 25% for ethanol, while adding grain‑based distillation to mitigate feedstock risk.
Analysts will watch how the diversified feedstock strategy and disciplined capex spending translate into sustained margin expansion and cash‑flow generation. The firm’s focus on high‑margin specialty chemicals, coupled with its IP pipeline and sustainability collaborations, positions it to capture growth in green chemistry and bio‑fuel markets, albeit with exposure to policy‑driven ethanol pricing and commodity volatility.
Original Description
Listen to 900+ live earnings calls with real-time transcript at AlphaStreet Intelligence
Events Calendar
Earnings Analysis
Live/On-demand Earnings Transcripts
Company Filings
0
Comments
Want to join the conversation?
Loading comments...